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ORIGINAL RESEARCH
Reactive Oxygen-Forming Nox5 Links Vascular 
Smooth Muscle Cell Phenotypic Switching 
and Extracellular Vesicle-Mediated Vascular 
Calcification
Malgorzata Furmanik,* Martijn Chatrou,* Rick van Gorp, Asim Akbulut, Brecht Willems, Harald Schmidt, Guillaume van Eys,  
Marie-Luce Bochaton-Piallat, Diane Proudfoot, Erik Biessen, Ulf Hedin, Ljubica Perisic, Barend Mees,  
Catherine Shanahan, Chris Reutelingsperger, Leon Schurgers
RATIONALE: Vascular calcification, the formation of calcium phosphate crystals in the vessel wall, is mediated by vascular 
smooth muscle cells (VSMCs). However, the underlying molecular mechanisms remain elusive, precluding mechanism-based 
therapies.
OBJECTIVE: Phenotypic switching denotes a loss of contractile proteins and an increase in migration and proliferation, whereby 
VSMCs are termed synthetic. We examined how VSMC phenotypic switching influences vascular calcification and the 
possible role of the uniquely calcium-dependent reactive oxygen species (ROS)-forming Nox5 (NADPH oxidase 5).
METHODS AND RESULTS: In vitro cultures of synthetic VSMCs showed decreased expression of contractile markers CNN-1 
(calponin 1), α-SMA (α-smooth muscle actin), and SM22-α (smooth muscle protein 22α) and an increase in synthetic 
marker S100A4 (S100 calcium binding protein A4) compared with contractile VSMCs. This was associated with increased 
calcification of synthetic cells in response to high extracellular Ca2+. Phenotypic switching was accompanied by increased 
levels of ROS and Ca2+-dependent Nox5 in synthetic VSMCs. Nox5 itself regulated VSMC phenotype as siRNA knockdown 
of Nox5 increased contractile marker expression and decreased calcification, while overexpression of Nox5 decreased 
contractile marker expression. ROS production in synthetic VSMCs was cytosolic Ca2+-dependent, in line with it being 
mediated by Nox5. Treatment of VSMCs with Ca2+ loaded extracellular vesicles (EVs) lead to an increase in cytosolic Ca2+. 
Inhibiting EV endocytosis with dynasore blocked the increase in cytosolic Ca2+ and VSMC calcification. Increased ROS 
production resulted in increased EV release and decreased phagocytosis by VSMCs.
CONCLUSIONS: We show here that contractile VSMCs are resistant to calcification and identify Nox5 as a key regulator of 
VSMC phenotypic switching. Additionally, we describe a new mechanism of Ca2+ uptake via EVs and show that Ca2+ induces 
ROS production in VSMCs via Nox5. ROS production is required for release of EVs, which promote calcification. Identifying 
molecular pathways that control Nox5 and VSMC-derived EVs provides potential targets to modulate vascular remodeling 
and calcification in the context of mineral imbalance.
GRAPHIC ABSTRACT: A graphic abstract is available for this article.
Key Words: calcium ◼ extracellular vesicles ◼ NADPH oxidase 5 ◼ phenotype ◼ vascular calcification
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Vascular calcification is the formation of calcium phosphate crystals in the blood vessel wall1 and is associated with a 3- to 4-fold increase in cardio-
vascular and all-cause mortality.2 Vascular calcification 
can be categorized based on its location in the vessel 
wall into intimal, predominantly associated with athero-
sclerosis, and medial, associated with aging, chronic 
kidney disease, and diabetes mellitus.3 The result of 
intimal calcification is an increased risk of plaque rup-
ture,4 which causes myocardial infarction and strokes.5 
Medial calcification in chronic kidney disease is attrib-
uted to an imbalance in calcium and phosphate metabo-
lism.6 The direct result of medial vascular calcification is 
blood vessel wall stiffening that leads to many cardio-
vascular complications, such as hypertension and aortic 
stenosis. These, in turn, give rise to cardiac hypertrophy, 
myocardial and lower-limb ischemia, congestive heart 
failure and can eventually result in death.7 To date, no 
early detection methods and no proven therapies exist 
to inhibit or reverse vascular calcification.
Vascular calcification is an active process regulated 
by vascular smooth muscle cells (VSMCs) via several 
mechanisms, including apoptosis,8 osteo/chondrogenic 
transdifferentiation,9 extracellular vesicle (EV) release,10 
and cellular senescence.11 In healthy arteries, most 
VSMCs of the tunica media maintain a contractile pheno-
type, which enables them to regulate vascular tone and 
maintain hemodynamic balance. Physiological or patho-
logical changes may demand adaptation of the involved 
arteries. Stress signals, such as oxidative or mechanical 
stress, cause VSMC phenotype to change. These dedif-
ferentiated or synthetic VSMCs are characterized by a 
decreased expression of contractile proteins (MLC [myo-
sin light chain], calponin [CNN-1], smoothelin, α-SMA [α-
smooth muscle actin], SM22α [smooth muscle protein 
22α]), increased proliferation and migration.12,13 The pro-
cess of dedifferentiation is termed phenotypic switch-
ing. Phenotypic switching is thought to precede the 
Nonstandard Abbreviations and Acronyms
α-SMA α-smooth muscle actin
BAPTA-AM  1,2-bis-(o-aminophenoxy)-ethane-
N,N,N,N-tetraacetic acid
CNN-1 calponin 1
EV extracellular vesicle
hVSMC human VSMC
MLC myosin heavy and light chain
MYH myosin heavy chain
MYL myosin light chain
MYOCD myocardin
Nox5 NADPH oxidase 5
pVSMC porcine VSMC
ROS reactive oxygen species
SM22-α smooth muscle protein 22α
SMTN smoothelin
VSMC vascular smooth muscle cell
Novelty and Significance
What Is Known?
• Vascular calcification causes vascular stiffness that 
leads to cardiovascular complications. The amount of 
calcification correlates with atherosclerotic burden and 
it is prevalent in chronic kidney disease where a serum 
mineral imbalance occurs.
• Vascular calcification is mediated by vascular smooth 
muscle cells (VSMCs), which show high phenotypic 
plasticity.
• Extracellular vesicles (EVs) released by VSMCs con-
tribute to vascular calcification by providing calcifica-
tion nucleation sites.
What New Information Does This Article  
Contribute?
• Nox5 (NADPH oxidase 5) contributes to VSMC phe-
notypic switching. Synthetic (dedifferentiated) VSMCs 
are more prone to calcification than contractile VSMCs.
• EVs mediate Ca2+ entry into VSMCs in the con-
text of elevated extracellular Ca2+, via clathrin- and 
caveolin-mediated uptake, leading to rises in cytosolic 
Ca2+ levels.
• Ca2+-dependent Nox5 increases oxidative stress, 
which leads to increased EV release from VSMCs and 
subsequent calcification.
Understanding vascular calcification is important not 
only for chronic kidney disease, where VSMCs are 
directly exposed to elevated Ca2+ levels, but other vas-
cular diseases, where vascular remodeling and VSMC 
phenotypic switching occurs as a result of other 
mechanisms; for example, increased PDGF signal-
ing in settings such as atherosclerosis, aneurysm, and 
hypertension. Nox5 is a possible therapeutic target 
with broad clinical applications. EVs are are key con-
tributors to biomineralization processes, but the mech-
anisms associated with their release and function are 
poorly understood. Our study describes a new mecha-
nism of Ca2+ entry into the cell via EVs and identifies 
Nox5-generated oxidative stress as a major stimulus 
for EV release.
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development of vascular disease. In specific pathologies 
VSMCs have been shown to differentiate even further 
and give rise to other cell types in the vessel wall includ-
ing macrophages14 and osteo/chondrogenic cells.15,16
Although phenotypic switching is thought to precede 
vascular disease, including vascular calcification, molecu-
lar events leading to the loss of contractile phenotype and 
mechanisms driving the synthetic VSMCs towards calci-
fication, are at present not fully understood. Therefore, 
in this study, we set out to investigate the relationship 
between VSMC phenotypic switching and vascular cal-
cification and the mechanisms that link these processes.
METHODS
The data that support the findings of this study are available 
from the corresponding author upon reasonable request.
An expanded Materials and Methods is available in the Data 
Supplement. Please see the Major Resources Table in the Data 
Supplement. 
Cell Culture, Treatments, and Transfections
Human and porcine aortic VSMCs (hVSMCs and pVSMCs) 
were derived from tissue explants and cultured as described 
previously.17,18 Collection, storage, and use of tissue and 
human aortic samples were performed in agreement with 
the Dutch Code for Proper Secondary Use of Human Tissue. 
HASMC66 cell line was cultured as described previously.19 
Each experiment was carried repeated in VSMCs from at least 
3 different donors. VSMCs in passages 5 to 12 were used. 
Heparin, PDGF-BB (platelet derived growth factor subunit B), 
GKT136901, VAS2870, 1,2-bis-(o-aminophenoxy)-ethane-
N,N,N,N-tetraacetic acid (BAPTA-AM), dynasore, and H2O2 
were used at concentrations stated in the figure legends. For 
calcification assays VSMCs were treated with control (1.8 
mmol/L Ca2+) or high calcium (3.6 mmol/L or 5.4 mmol/L 
CaCl2) medium. Calcification was measured as previously 
described.8 hVSMCs were transduced with lentiviral vectors 
Nox5 (NADPH oxidase 5)-β and green fluorescent protein 
(GFP) sequences for 48 hours. SiRNA (S103243856, Qiagen) 
transfection was performed using a Basic Smooth Muscle Cells 
Nucleofector Kit (Lonza) for 24 hours.
Cell Assays
pVSMC proliferation was measured real-time using the xCEL-
Ligence System (ACEA Biosciences). Reactive oxygen species 
(ROS) were quantified with Amplex red or DCFDA. Cytosolic 
Ca2+ was measured using Fluo-4-AM in Cytation3 (Biotek). 
Live single-cell imaging of cytosolic Ca2+ was performed by 
monitoring Fura-2 fluorescence using an Olympus Cell^R 
imaging system as described previously.20
Immunoblotting, Quantitative Reverse 
Transcriptase Polymerase Chain Reaction, and 
Immunofluorescence
VSMC RNA was reverse transcribed using Mu-MLV reverse 
transcriptase (Invitrogen) and the SYBR quantitative 
polymerase chain reaction assay (BioRad) according to manu-
facturer’s protocol. Immunoblotting and immunofluorescence 
were performed as previously described.21
The BiKE Cohort
Patients undergoing surgery for symptomatic (S) or asymp-
tomatic (AS), high-grade (>50% NASCET [North American 
Symptomatic Carotid Endarterectomy Trial]) carotid stenosis 
at the Department of Vascular Surgery, Karolinska University 
Hospital, Sweden, were consecutively enrolled in the study and 
clinical data recorded on admission.22 All samples were col-
lected with informed consent from patients or organ donors’ 
guardians. All human studies were approved by the regional 
Ethical Committees. The microarray data set is available from 
Gene Expression Omnibus (GSE21545).
Immunohistochemistry
Human coronary artery sections were collected during autopsy from 
20 patients aged 47 to 86 years, who died from noncardiac causes. 
Autopsy was performed 6 to 9 hours after death (Department of 
Pathology, Academic Hospital Maastricht, Maastricht). Tissue col-
lection was approved by the Maastricht Pathology Tissue Collection 
committee. The Medical Ethics Committee of the Maastricht 
University approved the study protocol and all subjects gave their 
informed consent in writing. Immunohistochemical staining was 
performed as described elsewhere.23
EV Isolation and Quantification
EVs were isolated by differential ultracentrifugation as pre-
viously described17 from HASMC6624 cells, pVSMCs, and 
hVSMCs. Quantification of EVs secreted in the cell culture 
media was performed using a bead capture assay, as previ-
ously described.25
Phagocytosis of EVs and CFSE Loading
EVs (15 μg protein), collected from HASMC66, were labeled 
with CFSE (carboxyfluorescein succinimidyl ester) for 30 min-
utes at 37°C and incubated with VSMCs. After incubation, cells 
were trypsinized, washed, and measured by flow cytometry 
(Acuri C6, BD biosciences).
Statistical Analysis
Data are shown as mean±SD and were obtained in 3 or more 
independent experiments. Normality of all data was tested 
using the Shapiro-Wilk test (for n≥4) or ascertained based on 
previous reports in literature (for n=3). If data were normally 
distributed, statistical significance was tested with t test, one-
sample t test, and 1-way ANOVA with Bonferroni post hoc 
for experiments with 2 and more groups, respectively. If data 
were not normally distributed, the Mann-Whitney, Wilcoxon 
signed-rank test, and Kruskal-Wallis with Dunn multiple com-
parisons tests were used. The exact test used for each data 
set is mentioned in figure legends. Statistical analysis was per-
formed using using GraphPad Prism 8.2.0. *P<0.05, **P<0.01, 
and ***P<0.001. No corrections for multiple testing were made 
across tests. Representative images for figures, which best 
reflected the data, were selected manually.
D
ow
nloaded from
 http://ahajournals.org by on N
ovem
ber 3, 2020
OR
IG
IN
AL
 R
ES
EA
RC
H
Furmanik et al Role of Nox5 in VSMC Phenotypic Switching
914  September 11, 2020 Circulation Research. 2020;127:911–927. DOI: 10.1161/CIRCRESAHA.119.316159
Pearson correlations were used to calculate the association 
between mRNA expression of Nox5 and other markers from 
the BiKE plaque microarray data set. Significance was consid-
ered when P<0.05.
RESULTS
Phenotypic Switching of VSMCs In Vitro Is 
Associated With Calcification Due to Increased 
ROS Production
Cultured VSMCs display progressive loss of contrac-
tile proteins, shifting towards a synthetic phenotype.26 
To study the relationship between VSMC phenotype 
and calcification in vitro we used 2 model systems: (1) 
pVSMCs isolated as distinct populations of contractile 
or synthetic cells18 and (2) hVSMCs treated with hepa-
rin or PDGF-BB to induce the contractile or synthetic 
phenotype, respectively.18,27 We confirmed that contrac-
tile pVSMCs express higher levels of contractile mark-
ers CNN-1 and α-SMA (Figure 1A) than synthetic cells. 
As previously described,18 the morphology of the cells 
differed, with synthetic cells being more rhomboid and 
contractile cells elongated. Next, we demonstrated that 
the phenotype switch is reversible, as treatment of con-
tractile pVSMC with PDGF-BB caused a loss of α-SMA 
(contractile versus synthetic P=0.0313, contractile ver-
sus contractile + PDGF P=0.022), SM22α (contractile 
versus synthetic P=0.0006, contractile versus contrac-
tile + PDGF P=0.0105) and CNN-1 (contractile versus 
synthetic P=0.0001, contractile versus contractile + 
PDGF P=0.0001) expression and a concomitant gain 
of S100A4 (S100 calcium binding protein A4) expres-
sion (contractile versus synthetic P=1.7×10−17, contrac-
tile versus contractile + PDGF P=0.0001), a synthetic 
marker (Figure 1B through 1F).28 Conversely, treat-
ing synthetic pVSMCs with heparin led to upregu-
lated α-SMA (synthetic versus synthetic + heparin 
P=0.0013), SM22-α (synthetic versus synthetic + hepa-
rin P=0.0061), and CNN-1 (synthetic versus synthetic 
+ heparin P=0.0070) and decreased S100A4 expres-
sion (synthetic versus synthetic + heparin P=1.7×10−6) 
indicating a switch towards a contractile phenotype. 
Similar effects of PDGF-BB and heparin were observed 
in hVSMCs (Figure IA and IB in the Data Supplement). 
Additionally, synthetic VSMCs showed higher rates of 
proliferation (Figure 1G, P=0.0079; Figure IC in the 
Data Supplement, P=0.0045) than contractile VSMCs.
To accelerate the process of calcification in vitro, 
we cultured VSMCs in medium with an increased Ca2+ 
concentration. Contractile pVSMCs showed no signifi-
cant Ca2+ crystal formation, whereas synthetic pVSMCs 
exposed to calcifying conditions calcified significantly 
(Figure 2A, P=1 for 1.8 mmol/L, P=1.3×10−5 for 5.4 
mmol/L; Figure ID in the Data Supplement, P=1 for 1.8 
mmol/L, P=1.7×10−10 for 5.4 mmol/L). The increased 
calcification could be partly rescued by reversing pVSMC 
phenotype with heparin (Figure 2B, P=2.4×10−5 and 
Figure 2C, P=1.9×10−5). This suggests that the rate 
of calcification is linked to VSMC phenotype. A similar 
dependency of calcification on phenotype was observed 
in hVSMCs (Figure IE in the Data Supplement, P=1 for 
1.8 mmol/L, P=9×10−5 for 3.6 mmol/L, P=0.0027 for 
5.4 mmol/L; Figure IF in the Data Supplement, P=1 for 
1.8 mmol/L, P=7×10−5 for 3.6 mmol/L, P=8.8×10−5 for 
5.4 mmol/L).
We next set out to investigate the mechanisms, which 
could explain the different rates at which contractile 
and synthetic VSMCs calcify. Expression of osteogenic 
genes, classically associated with calcification, was not 
different between the phenotypes at baseline, except a 
higher expression of matrix Gla protein (MGP) mRNA in 
contractile pVSMCs compared with synthetic pVSMCs 
(Figure IG and IH in the Data Supplement P=2.2×10−7 
for α-SMA, P=0.585 for RUNX2 (RUNX family tran-
scription factor 2), P=0.609 for Osterix, P=0.266 for 
BMP2 (bone morphogenetic protein 2), P=5.6×10−6 
for MGP). Therefore, we focused on oxidative stress, 
which is a known mediator of vascular calcification.29 
Contractile and synthetic pVSMCs produced comparable 
amounts of H2O2 under noncalcifying conditions (Fig-
ure 2D, P=0.1407). However, exposure to high Ca2+ lev-
els resulted in increased production of H2O2 by synthetic 
pVSMCs (Figure 2D, P=0.0020). This suggested that in 
these cells the rise in ROS production is Ca2+-depen-
dent. In support of this notion, antioxidant N-acetylcys-
teine was able to decrease Ca2+-induced calcification of 
synthetic pVSMCs (Figure 2E, P=0.0118).
To examine the mechanism responsible for increased 
ROS in synthetic VSMCs, we compared expression of 
3 Nox (NADPH oxidase) enzymes between the pheno-
types. We found that Nox1 expression was similar in both 
phenotypes (P=0.1590), but both Nox4 and Nox5 were 
significantly upregulated (P=0.02399 and P=0.0107, 
respectively) in synthetic pVSMCs compared with con-
tractile pVSMCs on mRNA level (Figure 2F). However, 
only Nox5 expression was significantly upregulated 
when measured by Western blotting (P=0.0702 for 
Nox4, P=0.0127 for Nox5; Figure 2G through 2J, Figure 
II in the Data Supplement).
Nox5 is Highly Expressed in Synthetic VSMCs and 
Mediates Phenotypic Switching and Calcification
We next set out to investigate whether Nox4 and Nox5 
were involved in synthetic phenotype-related calcification 
in our model. Since Nox4 was expressed at lower levels 
than Nox5 and we excluded a role for Nox4 in VSMC cal-
cification (Figure IIA in the Data Supplement, P=0.4848), 
we focused on Nox5. First, we confirmed that switching 
contractile pVSMCs to synthetic cells with PDGF signifi-
cantly increased expression of Nox5 mRNA (Figure 3A, 
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Figure 1. Phenotypic switching of porcine vascular smooth muscle cells (pVSMCs) is associated with changes in contractile 
gene expression and proliferation.
A, Brightfield images and immunocytochemical staining of contractile proteins in synthetic and contractile pVSMCs showing differences in 
cell morphology and CNN-1 (calponin 1) and α-SMA (α-smooth muscle actin) expression. Scale bars: 50 μm (immunocytochemistry), 1 mm 
(brightfield). Representative images from 3 independent experiments. B–F, Western blotting and quantification of contractile proteins and 
synthetic marker in contractile cells treated with PDGF and synthetic cells treated with heparin, showing phenotypic switching was partially 
reversible. Cells were grown in DMEM with 10% FBS with 20 ng/mL PDGF for 2 d or 200 U/mL heparin for 5 d. Molecular weight markers in 
all Western blots indicated in kDa. Graphs show pooled data from 3 independent experiments, some performed in triplicate. Statistical significance 
was tested using the Wilcoxon signed-rank test (C) or the Mann-Whitney U test (D and E) or t test (F). G, Proliferation of pVSMCs was measured 
using the xCELLigence system, which measures the impedance of cells adhering to an electrode-covered surface. Synthetic cells show increased 
proliferation. Data from one representative experiment performed in triplicate. Statistical significance was tested using t test.
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Figure 2. Synthetic phenotype is associated with increased calcification, reactive oxygen species (ROS) production, and Nox 
(NADPH oxidase) expression.
Calcification was induced by incubation with elevated Ca2+ concentrations (5.4 mmol/L) in DMEM with 0.5% FBS and quantified using an 
o-cresolphthalein colorimetric assay. A, Synthetic porcine vascular smooth muscle cells (pVSMCs) showed significant calcification in contrast 
to contractile cells after 48 h. Statistical significance was tested using the Mann-Whitney U test. Pooled data from 3 independent experiments 
performed in duplicate. B, Treating synthetic pVSMCs with heparin decreased calcification after 48 h. Statistical significance was tested with 
t test. Pooled data from 3 independent experiments performed in duplicate. C, Treating contractile pVSMCs with PDGF for 48 h increased 
calcification. Statistical significance was tested with t test. Pooled data from 3 independent experiments performed in duplicate. D, Synthetic 
pVSMCs treated with 5.4 mmol/L Ca2+ in 0.5% FBS for 22 h produced more H2O2 than contractile cells. H2O2 production was measured using 
Amplex red. Statistical significance was tested with t test. Data from one representative experiment performed in quadruplicate. E, Scavenging 
H2O2 with 1 mmol/L N-acetylcysteine (NAC) decreased calcification of synthetic pVSMCs treated with 5.4 mmol/L Ca
2+ in 0.5% FBS for 48 
h. Statistical significance was tested using the Mann-Whitney U test. Pooled data from 3 independent experiments performed in triplicate or 
quadruplicate. F, Quantitative polymerase chain reaction (QPCR) analysis showed increased Nox4 and Nox5 expression in synthetic pVSMCs at 
baseline. Statistical significance was tested with t tests. Pooled data from 3 independent experiments carried out in triplicate or quadruplicate. 
G–J, Western blotting and quantification of Nox4 and Nox5 in contractile and synthetic pVSMCs. Molecular weight markers in all Western blots 
indicated in kDa. Statistical significance was tested with t tests (H and J). Data from one representative experiment performed in triplicate. 
Statistical significance was tested using t test.
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Figure 3. Nox5 (NADPH oxidase 5) mediates phenotypic switching and vascular smooth muscle cell (VSMC) calcification.
A and B, qPCR analysis of Nox5 mRNA expression in synthetic porcine VSMCs (pVSMCs) treated with heparin (200 U/mL, 5 d) and contractile 
pVSMCs treated with PDGF (20 ng/mL, 2 d). Expression was normalized to β-actin. Statistical significance was tested using t test. Pooled data 
from 2 independent experiments performed in duplicate. C–G, SiRNA knockdown (24 h) of Nox5 increased expression of contractile markers 
in human VSMCs (hVSMCs) (Western blot and quantifications). Molecular weight markers in all Western blots indicated in kDa. Statistical 
significance was tested using the Mann-Whitney U test (D), Wilcoxon signed-rank test (F), or one-sample t test (E and G). Pooled data from 4 to 
8 independent experiments. H, SiRNA knockdown (24 h) of Nox5 decreased calcification of hVSMCs (Continued )
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P=0.0002), whereas switching synthetic pVSMCs with 
heparin to contractile cells decreased Nox5 levels (Fig-
ure 3B, P=0.0002). Knockdown of Nox5 (P=0.0022) in 
hVSMCs resulted in increased expression of contractile 
markers CNN-1 (P=0.0319), p-MLC (P=0.0008), and 
SM22-α (P=0.0156, Figure 3C through 3G) and decreased 
calcification (Figure 3H, P=0.0018). Conversely, over-
expression of Nox5 (P=0.0084) resulted in decreased 
expression of contractile markers p-MLC (P=0.0010) and 
CNN-1 (P=0.0002) as well as synthetic marker S100A4 
(P=0.0028, Figure 3I through 3M, Figure IIB in the Data 
Supplement) and increased calcification (P=0.0068, Fig-
ure 3N and 3O). Additionally, H2O2 treatment decreased 
p-MLC (P=0.0005) and S100A4 (P=0.0024) expression in 
hVSMCs (Figure IIC in the Data Supplement). These results 
imply that signals which induce phenotype changes, do so 
via decreased or increased expression of Nox5 and result-
ing changes in ROS levels. Interestingly, our results suggest 
that upregulation of S100A4 in synthetic cells occurs via 
mechanisms other that Nox5-mediated ROS upregulation.
Ca2+-Dependent Oxidative Stress Mediates 
pVSMC Calcification
Nox5 is known to be activated by binding of cytosolic 
Ca2+ to its EF hand,30 therefore, we hypothesized that it is 
the molecular link between increased extracellular Ca2+, 
and ROS-dependent calcification of synthetic VSMCs. 
First, we investigated EV-mediated uptake as a pos-
sible mechanism by which increased extracellular Ca2+ 
can increase cytosolic Ca2+. To this end, hVSMCs were 
treated with dynasore, an inhibitor of clathrin- and caveo-
lin-dependent EV uptake31 in the presence of high Ca2+. 
Dynasore blocked the increase in cytosolic Ca2+ caused 
by the high Ca2+ treatment (P=0.0241 for control versus 
3.6 mmol/L Ca2+ and P=0.0190 for 3.6 mmol/L Ca2+ 
versus 3.6 mmol/L Ca2+ + dynasore, P=0.059 for con-
trol versus ionomycin; Figure 4A), suggesting that Ca2+ 
enters the cells via EVs. Ionomycin, which causes a rapid 
influx of Ca2+ into the cells, was used as a positive control. 
In line with this, EVs isolated from cells incubated with 3.6 
mmol/L Ca2+ accumulated significantly higher (1 versus 
4.68±1.55, P=0.0497) Ca2+ compared with EVs isolated 
from cells treated with normal calcium (1.8 mmol/L Ca2+; 
Figure 4B). When EVs were isolated from cells treated 
in normal Ca2+, but later incubated with high Ca2+ in the 
absence of cells, they also accumulated Ca2+ (1 versus 
3.71±2.32, P=0.1812; Figure 4C) suggesting that Ca2+ 
loading into EVs happens outside of the cells. Additionally, 
we performed a more sensitive cytosolic Ca2+ assay in 
single cells. VSMCs were treated with high Ca2+, which 
resulted in an insignificant increase in cytosolic Ca2+ in 
1 hour, compared with control (Figure 4D). Interestingly, 
when VSMCs cultured in medium with normal Ca2+ were 
treated with EVs isolated from VSMCs treated with high 
Ca2+, transient increases in cytosolic Ca2+ were observed 
(Figure 4E). In VSMCs treated with EVs isolated from 
VSMCs incubated with normal Ca2+ no such increases 
were observed. These observations suggest that EVs 
generated in a high Ca2+ environment induce a cytosolic 
Ca2+ rise in VSMCs. Additionally, dynasore inhibited calci-
fication of VSMCs (P=0.0213; Figure 4F). This suggests 
that Ca2+ entry via EVs contributes to VSMC calcification.
Next, we set out to investigate whether this rise of cyto-
solic Ca2+ leads to increased ROS production and calcifi-
cation. First, we confirmed that overexpression of Nox5 
in hVSMCs, which induced synthetic differentiation, lead 
to increased ROS production (P=0.0033; Figure 4G) and 
that siRNA knockdown of Nox5 lead to decreased ROS 
production (P=0.0005; Figure 4H). Then, we demon-
strated that cytosolic Ca2+ chelator BAPTA-AM blocked 
the increase in H2O2 production by synthetic pVSMCs 
(P=0.0007; Figure 4I). H2O2 production was also blocked 
by the Nox inhibitor GKT136901 (P=4.6×10−5; Figure 4I). 
Moreover, Nox inhibitors GKT136901 and VAS2870 
as well as BAPTA-AM decreased VSMC calcification 
(P=0.0007 for GKT, P=4.6×10−5 for BAPTA, P=0.0367, 
P=0.0053, P=0.0310, and P=0.2894 for 1, 2, 5, and 10 
μmol/L VAS, respectively; Figure 4J and 4K, Figure IID in 
the Data Supplement, Figure IIE in the Data Supplement 
hVSMCs, P=0.0052). Taken together these results show 
that cytosolic Ca2+-Nox5-dependent ROS production is 
required for calcification of synthetic VSMCs.
Nox5-Mediated Oxidative Stress Induces EV 
Release and Inhibits Phagocytosis in Synthetic 
VSMCs
EVs have recently been shown to play an important role in 
VSMC calcification.25 Therefore, we set out to investigate 
whether EVs could be the mediators of Ca2+-Nox5-ROS-
induced calcification of synthetic VSMCs. We first con-
firmed that externally added EVs (Figure IIIA in the Data 
Supplement) increased calcification of a collagen matrix 
(P=0.0005; Figure 5A) and of synthetic (P=0.0055 for 
control versus Ca2+, P=0.0002 for control versus Ca2+ + 
EVs, P=0.0092 for Ca2+ versus Ca2+ + EVs; Figure 5B) 
and contractile pVSMCs (P=0.981 for control versus Ca2+, 
Figure 3 Continued. (calcification was induced with 5.4 mmol/L Ca2+ in 2.5% FBS for 5 d). Statistical significance was tested using t test. 
Data from a representative experiment carried out in quadruplicate. I–M, Nox5 overexpression using a lentivirus resulted in decreased contractile 
protein expression and decreased S100A4 (S100 calcium binding protein A4) expression in hVSMCs (Western blotting and quantification). Nox5 
was quantified using immunocytochemistry on the Cytation 3 imaging reader. Statistical significance was tested using t tests (I, K–M). Data 
from a representative experiment performed in quadruplicate. Molecular weight markers in all Western blots indicated in kDa. N and O, Nox5 
overexpression increased calcification of hVSMCs treated with 5.4 mmol/L Ca2+ in 2.5% FBS for 3 d, measured using o-cresolphthtalein and 
visualized with Alizarin Red S. Statistical significance was tested using t test. Data from a representative experiment performed in quadruplicate.
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Figure 4. Ca2+-dependent oxidative stress mediates calcification of synthetic vascular smooth muscle cells (VSMCs).
A, Human VSMCs (hVSMCs) were treated with 3.6 mmol/L Ca2+, 40 μmol/L dynasore, or 1 μmol/L ionomycin for 4 h in M199 with 0.5% FBS. 
Cytosolic Ca2+ was measured using Fluo-4-AM in Cytation 3 imager. Graph shows pooled data from 3 independent experiments. Statistical 
significance was tested using the Kruskal-Wallis test. Pooled data from 3 experiments performed in triplicate. B, hVSMCs were treated with 
M199 with 2.5% FBS with normal (1.8 mmol/L) or high (3.6 mmol/L) Ca2+ for 48 h. No calcification was observed. Extracellular vesicles (EVs) 
were isolated by ultracentrifugation, Ca2+ content in EVs was quantified using an o-cresolphthalein colorimetric assay and normalized to protein 
content. Pooled data from 3 experiments, significance tested using one-sample t test. Pooled data from 3 experiments. C, Medium was collected 
from 106 hVSMCs grown in M199 with 20% FBS and incubated with CD63 (CD63 molecule)-coupled beads overnight to capture EVs. Next, 
the EV bead pool was aliquoted and aliquots were treated with 3.6 mmol/L Ca2+ or normal Ca2+, washed and Ca2+ content was quantified using 
an o-cresolphthalein colorimetric assay. Graph shows pooled data from 3 experiments. Statistical significance was tested using one-sample 
t test. Pooled data from 3 experiments. D, hVSMCs were loaded with Fura-2-AM which was alternately excited at 340 and 380 nm and the 
ratiometric emission, corresponding to cytosolic Ca2+ concentration, is presented. Cells were treated with normal (1.8 mmol/L) or high (5.4 
mmol/L) extracellular Ca2+ after 5 min of live monitoring and continued monitoring up to 60 min. Results shown are responses for 2 individual 
cells, representing ≈20 cells from 2 independent experiments. E, As for D, but hVSMCs were treated with EVs isolated by ultracentrifugation from 
hVSMCs treated for 48 h with medium containing 1.8 or 3.6 mmol/L Ca2+. Some cells showed clear oscillatory cytosolic Ca2+ responses to EVs 
isolated from 3.6 mmol/L Ca2+ conditions but no cells showed responses to EV from 1.8 mmol/L Ca2+ conditions. (Continued )
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P=0.0030 for control versus Ca2+ + EVs, P=0.0086 for 
Ca2+ versus Ca2+ + EVs; Figure IIIB in the Data Supple-
ment). This was further confirmed in a Boyden chamber 
experiment with pVSMC in the upper chamber and a col-
lagen coating in the lower chamber. Synthetic pVSMCs 
in the upper chamber caused significantly more calcifica-
tion in the lower chamber as compared with contractile 
VSMCs (P=0.0056; Figure IIIC in the Data Supplement). 
Additionally, dynasore attenuated calcification induced 
by externally added EVs (P=4.4×10−7 for control versus 
Ca2+ + EVs, P=0.0001 for Ca2+ + EVs versus Ca2+ + 
EVs + dynasore; Figure 5C). Quantification of EVs using 
a bead capture assay showed that synthetic hVSMCs 
released significantly more EVs than contractile hVSMCs 
(P=0.0008 for control versus heparin, P=0.0074 for 
control versus PDGF; Figure 5D). These results suggest 
that synthetic VSMCs secrete more EVs, which leads to 
increased calcification.
We next showed that high extracellular Ca2+ levels 
(which lead to increased ROS production in synthetic 
cells, Figure 2D) induced EV release (P=0.0109; Fig-
ure 5E). Additionally, H2O2 dose-dependently enhanced 
EV release (P=0.9669 for 25 μmol/L H2O2, P=2.1×10
−5 
for 50 μmol/L H2O2; Figure 5F). To investigate whether 
EV release is mediated by Nox5, we treated hVSMCs with 
pan-Nox inhibitor GKT136901 and observed decreased 
EV release in the presence of Ca2+ (P=0.0013; Fig-
ure 5G, Figure IIID in the Data Supplement). Conversely, 
overexpression of Nox5 in hVSMCs, which leads to 
increased ROS production (Figure 4G), induced a 5-fold 
increase in EV release (P=0.0001; Figure 5H).
Extracellular levels of EVs are the result of a balance 
between secretion and uptake and we showed that ROS 
induced secretion of EVs. Therefore, we investigated 
whether uptake of EVs by VSMCs is influenced by ROS. 
First, we confirmed that EVs secreted by VSMCs present 
phosphatidylserine, a phagocytosis signal19 (Figure IIIE in 
the Data Supplement) and that CFSE-labeled EVs were 
phagocytosed when added to synthetic hVSMCs in EV-free 
medium. Significantly more uptake occurred at 37°C than 
at 4°C indicative of an active phagocytic process (Figure 
IIIF in the Data Supplement). Next, we showed that H2O2 
inhibited phagocytosis of EVs (P=0.0152; Figure 5I). Taken 
together these results suggest that Ca2+-Nox5- induced 
ROS lead to increased release and inhibited uptake of EVs, 
which causes their net accumulation and increased calcifi-
cation in the extracellular environment.
Nox5 Is Expressed in Synthetic VSMCs in 
Human Vascular Disease Tissues
To examine the relationship between Nox5 expression 
and VSMC markers in human vascular disease con-
text, we analyzed global transcriptomic data from 127 
advanced human atherosclerotic plaques (Table, Figure 
IV in the Data Supplement). Nox5 mRNA expression 
showed a positive correlation with contractile mark-
ers α-SMA, SMTN (smoothelin), and MYL (myosin light 
chain). There was no correlation with CNN-1, SM22-α, 
or MYOCD (myocardin) and a negative correlation with 
MYH11 (myosin heavy chain), one of the first markers lost 
in dedifferentiating VSMCs.32 Unexpectedly, there was 
a negative correlation with S100A4 and KLF-4, which 
promote synthetic differentiation. We also examined EV-
related gene expression and found a negative correla-
tion with EV/multivesicular body markers CD63 (CD63 
molecule), CD81 (CD81 molecule), and TSG101 (tumor 
susceptibility 101), but strong positive correlations with 
CD9 (CD9 molecule) and enzyme regulating EV release 
SMPD3 (sphingomyelin phosphodiesterase 3). Addition-
ally, there was a positive correlation with PDGF expres-
sion. Since atherosclerotic plaques are comprised many 
other cell types, we also examined Nox5 expression in 
correlation with markers of other cell types (Table I in the 
Data Supplement). Nox5 expression negatively correlated 
with endothelial cell, platelet, lipid-laden foam cell, macro-
phage, and some lymphocyte markers (CD8B [CD8b mol-
ecule], CD4 [CD4 molecule], and FOXP3 [forkhead box 
P3]). Positive correlation was observed with other lympho-
cyte markers (ITGAE [integrin subunit α E], CD80 [CD80 
molecule] , and CD86 [CD86 molecule]).
To further assess whether Nox5-dependent phenotype 
switching occurred in human vasculature we localized syn-
thetic and contractile markers and Nox5 in human arteries 
on protein level (Figure 6). Immunohistochemical stain-
ing of human coronary artery samples showed extensive 
Nox5 staining in regions with α-SMA expression, indicat-
ing the presence of VSMCs, but with low expression of 
contractile marker CNN-1 and high expression of syn-
thetic marker S100A4. Some Nox5 staining was present 
Figure 4 Continued. Results shown are responses for 2 individual cells, representing ≈15 cells from 2 independent experiments. F, Inhibiting 
EV uptake with dynasore decreased calcification. hVSMCs were treated in DMEM with 0.5% FBS and 3.6 mmol/L Ca2+ with or without 8 μmol/L 
dynasore for 48 h. Representative data from 3 experiments. Statistical significance was tested using t test. Pooled data from 2 experiments 
performed in triplicate. G, Overexpression of Nox5 (NADPH oxidase 5) induced an increase in cytosolic reactive oxygen species (ROS) measured 
using the DCFDA probe. Statistical significance was tested using t test. Data from a representative experiment performed in triplicate. H, Nox5 
knockdown decreased ROS production in hVSMCs. Pooled data from 2 experiments. Statistical significance was tested using t test. Pooled 
data from 2 experiments (in triplicate and inquadruplicate). I, Both Nox (NADPH oxidase) inhibitor GKT136901 (10 μmol/L) and cytosolic Ca2+ 
chelator 1,2-bis-(o-aminophenoxy)-ethane-N,N,N,N-tetraacetic acid (BAPTA; 2 μmol/L) decreased H2O2 production measured with Amplex red 
in synthetic cells treated with 5.4 mmol/L Ca2+ in 0.5% FBS. Statistical significance was tested using t tests. Pooled data from 3 experiments 
performed in triplicate. J and K, GKT136901 (10 μmol/L) and BAPTA (2 μmol/L) decreased calcification of synthetic porcine vascular smooth 
muscle cells (pVSMCs) treated with 5.4 mmol/L Ca2+ in 0.5% FBS for 48 and 36 h, respectively. Statistical significance was tested using t tests. 
Data from representative experiment in quadruplicate (J) and pooled data from 3 experiments in triplicate (K).
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Figure 5. Nox5 (NADPH oxidase 5)-dependent oxidative stress increases extracellular vesicle (EV) release and inhibits 
phagocytosis.
A, EVs isolated by ultracentrifugation from HASMC66 cultured in normal medium (7.5 μg/mL protein concentration) increased calcification of a 
collagen matrix in the absence of cells (calcification was induced with 5.4 mmol/L Ca2+ in 0.5% of EV-free FBS for 24 h). Statistical significance was 
tested using t test. Data from representative experiment in quadruplicate. B, EVs isolated from HASMC66 cells (15 μg/mL) increased calcification of 
synthetic porcine vascular smooth muscle cells (pVSMCs). Statistical significance was tested using ANOVA with Bonferroni post hoc test. Data from 
representative experiment in triplicate. C, EV uptake inhibitor dynasore attenuated calcification induced by externally added EVs. Equal numbers of 
hVSMCs were incubated with 5.4 mmol/L Ca2+ and EVs for 48 h in medium with 0.5% FBS. Calcification was quantified using o-cresolphthalein assay 
and visualized using Alizarin Red S staining. Statistical significance was tested using ANOVA with Bonferroni post hoc test. Data from representative 
experiment in quadruplicate. D, Contractile hVSMCs (treated with 200 U/mL heparin for 5 d) secreted fewer EVs than synthetic hVSMCs (treated 
with 20 ng/mL PDGF for 2 d). EVs were captured with anti-CD63 (CD63 molecule)-coupled beads, detected with a fluorescently labeled anti-CD81 
(CD81 molecule) antibody and quantified using flow cytometry. Statistical significance was tested using t tests. Pooled data from 2 experiments in 
triplicate. E, 5.4 mmol/L Ca2+ increased EV release in hVSMCs (in 2.5% of EV-free FBS, 48 h). Statistical significance was tested using t test. Data 
from representative experiment in quadruplicate. F, H2O2 increased EV release in hVSMCs (2.5% FBS, 24 h). Statistical significance was tested using 
ANOVA with Bonferroni post hoc test. Pooled data from 3 experiments in duplicate. G, Nox (NADPH oxidase) inhibitor GKT136901 (10 μmol/L) 
decreased EV release in the presence of 5.4 mmol/L Ca2+ in hVSMCs (2.5% FBS, 24 h). Statistical significance was tested using t test. Pooled data 
from 3 experiments in quadruplicate. H, Nox5 overexpression in hVSMCs using a lentiviral vector increased EV release. Statistical significance was 
tested using t test. Data from representative experiment in quadruplicate. I, CFSE (carboxyfluorescein succinimidyl ester)-labeled EVs (15 μg/mL) from 
HASMC66 were added to hVSMCs pretreated with H2O2 for 20 h in 2.5% FBS. Uptake was quantified after 4 h by flow cytometry. H2O2 decreased 
EV uptake. Statistical significance was tested using the Kruskal-Wallis test. Data from representative experiment in triplicate.
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in the adventitia, suggesting possible expression of Nox5 
in other cell types. Taken together, these results support 
the notion that Nox5 is expressed in synthetic VSMCs in 
human vessels and that EV release is involved.
DISCUSSION
In the present study, we identify Nox5 as a key regulator 
of VSMC phenotype and calcification. We demonstrate 
that contractile VSMCs have low calcification capac-
ity and that switching towards a synthetic phenotype 
promotes calcification. We show that extracellular 
factors known to induce phenotype switching cause 
increased Nox5 expression. Subsequently, increased 
Nox5 expression then induces phenotypic switching to 
synthetic. We elucidate the mechanism by which syn-
thetic VSMCs are prone to calcification, showing that 
extracellular Ca2+ enters cells via EVs, which results 
in a cytosolic Ca2+ rise. This activates Nox5, which is 
responsible for increased ROS production. Increased 
ROS leads to decreased contractile marker expression, 
enhanced EV release, and decreased uptake, which pro-
motes calcification (Figure 7).
Table. Nox5 Expression Correlates With SMC Markers in Atherosclerotic Plaques
Cell Marker Pearson r 95% CI P (2-Tailed) P Value Summary
Smooth muscle MYH11 −0.2691 −0.4240 to −0.09884 0.0023 **
CNN-1 −0.0161 −0.1898 to 0.1586 0.8574 ns
MYOCD 0.1171 −0.05898 to 0.2862 0.1915 ns
SM22-α 0.1255 −0.05048 to 0.2940 0.1613 ns
α-SMA 0.3943 0.2356 to 0.5325 4.9×10−6 ****
MYL10 0.4328 0.2796 to 0.5644 3.8×10−7 ****
SMTN 0.6218 0.5014 to 0.7186 8×10−15 ****
MYL1 0.6692 0.5603 to 0.7554 7.7×10−18 ****
Synthetic S100A4 −0.313 −0.4620 to −0.1467 0.0003 ***
KLF-4 −0.3701 −0.5113 to −0.2093 1.9×10−5 ****
Extracellular vesicles CD63 −0.1774 −0.3411 to −0.0033 0.046 *
CD81 −0.3507 −0.4947 to −0.1880 5.7×10−5 ****
TSG101 −0.3624 −0.5047 to −0.2008 3.1×10−5 ****
SMPD3 0.6594 0.5482 to 0.7478 3.6×10−17 ****
CD9 0.7246 0.6299 to 0.7981 6×10−22 ****
Growth factor PDGFB 0.417 0.2611 to 0.5517 1.2×10−5 ****
Pearson correlations were performed to investigate the association between the transcriptomic expression levels of Nox5 and SMC markers, based on the microarray 
data from human plaques in the BiKE cohort, n=127. CNN-1 indicates calponin 1; MYH, myosin heavy chain; MYL, myosin light chain; MYOCD, myocardin; Nox5, NADPH 
oxidase 5; SM22-α, smooth muscle protein 22α; SMTN, smoothelin; and α-SMA, α-smooth muscle actin.
Figure 6. Nox5 (NADPH oxidase 5) is 
expressed in synthetic cells in human 
arteries.
Immunohistochemical staining of human coronary 
artery with atherosclerotic plaque. Vascular 
smooth muscle cells (VSMCs) were α-SMA (α-
smooth muscle actin)-positive. Nox5 was present 
in VSMCs expressing S100A4 (S100 calcium 
binding protein A4), but not contractile marker 
CNN-1 (calponin 1; black arrows). Figure shows 
representative images from a total of 20 coronary 
artery and aortic samples that were stained. Scale 
bars are 250 μm.
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Contractile VSMCs Are Resistant to 
Calcification
In the present study, we demonstrate that contractile 
VSMCs are resistant to calcification in vitro suggesting 
that switching towards a synthetic phenotype is required 
for mineralization. We propose that this is, in part, due 
to differences in Nox5 expression. We show that Nox5 
mRNA expression in advanced atherosclerotic plaques 
correlated with expression of some SMC markers and not 
of markers of other cell types. A negative correlation or no 
correlation was observed with CNN-1, SM22-α, MYOCD, 
and MYH11, suggesting that Nox5 is expressed in dedif-
ferentiated VSMCs. In this data set, we also observed a 
negative correlation of Nox5 expression with S100A4 
and KLF-4, previously associated with synthetic differ-
entiation.14,28 However, the atherosclerotic plaques in this 
study were of late stages (American Heart Association 
grade VI and VII). Therefore, it is possible that no active 
synthetic differentiation occurs at these stages, and the 
correlation is lost, although it may have been present dur-
ing earlier stages of atherogenesis. Additionally, the neg-
ative correlation of S100A4 with Nox5 expression is in 
line with our results showing that overexpression of Nox5 
or H2O2-induced oxidative stress downregulated expres-
sion of S100A4 protein in VSMCs. S100A4 is known to 
regulate cell proliferation and motility, but more recently, it 
has been shown to be released to the extracellular space 
where it has an important function in VSMC phenotype 
switching.33 Neither of the methods which we used 
(mRNA analysis in plaque samples or Western blot of 
cell lysates) would have measured extracellular S100A4 
protein accumulation, so its regulation by Nox5 and ROS 
cannot be fully excluded.
By immunohistochemistry, we have shown that Nox5 
expression in synthetic VSMCs in the vessel wall, consis-
tent with its role as a regulator of phenotypic switching. In 
line with this, Nox5 expression was previously shown to 
be highly upregulated in VSMCs in advanced human ath-
erosclerotic plaques,34 which are characterized by VSMC 
phenotypic switching and calcification. Additionally, 
polymorphisms in the Nox5 gene are linked to changes 
in blood pressure,35 which are associated with VSMC-
mediated vascular remodeling. It remains to be estab-
lished what causes the increase in Nox5 expression in 
synthetic VSMCs in the first place. Inflammation-related 
stimuli have been shown to regulate Nox5 expression,36 
however, this has not been investigated in the context of 
phenotypic switching.
We also found that contractile VSMCs had signifi-
cantly higher levels of MGP, an inhibitor of vascular calci-
fication. Carboxylated MGP is known to block both crystal 
formation and BMP signaling.37 An increased level of this 
inhibitor might offer another explanation to the observed 
resistance of contractile VSMCs to calcification.
Regulation of VSMC Phenotype by Nox5
We show here that Nox5 is a marker and (via increased 
ROS production) an inducer of the synthetic pheno-
type. Consistent with our findings, Nox5-derived ROS 
was previously identified as a driving force for coronary 
Figure 7. Regulation of vascular smooth muscle cell (VSMC) calcification by Nox5 (NADPH oxidase 5).
A, The synthetic phenotype is associated with increased Nox5 expression, which further exacerbates phenotypic switching to synthetic. 
Extracellular Ca2+ enters cells via clathrin- and caveolin-dependent uptake of extracellular vesicles (EVs), which results in a cytosolic Ca2+ 
rise. This activates Nox5, which is responsible for increased reactive oxygen species (ROS) production. Increased ROS leads to enhanced EV 
release and decreased phagocytosis. An increased amount of EVs in the extracellular matrix promotes calcification. B, Contractile VSMCs 
dedifferentiate to synthetic VSMCs. This process is induced by PDGF, high Ca2+ and mediated by Nox5. Synthetic VSMCs undergo further 
changes, including apoptosis and osteogenic differentiation, secrete increased amounts of extracellular matrix (ECM) and EVs. All these 
processes lead to increased calcification.
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SMC migration, consistent with the synthetic phenotype, 
via upregulation of intermediate-conductance Ca2+ acti-
vated K+ channels.38 Additionally, Nox5-produced ROS 
have been shown to mediate PDGF-induced prolifera-
tion of VSMCs.39 However, in other contexts ROS were 
shown to be required for VSMC contractile differentia-
tion40 and maintenance of the contractile phenotype via 
Nox4-derived ROS.41,42 ROS are also required for VSMC 
contraction.43 It is possible that the discrepancy between 
our results and previous studies is due to different Nox 
enzymes mediating divergent effects. The overall out-
come for the cells would then depend on the balance 
between the activity of these enzymes. Another possibil-
ity is that ROS form a negative feedback loop for phe-
notype control, with synthetic cells producing more ROS, 
which among other effects, help the cells regain a con-
tractile phenotype. This is in line with research showing 
that Nox5 is inactivated by oxidation of its Ca2+-binding 
domain.44 These control mechanisms possibly become 
dysregulated in vascular pathologies when many adverse 
factors are at play, as oxidative stress is a causative fac-
tor in vascular disease.45
Our results with regards to Nox5-produced ROS pro-
moting a synthetic phenotype in VSMCs are contrary to 
recent findings by Montezano et al.46 In this study, human 
Nox5 was constitutively expressed under the SM22-
α promoter in mice, as Nox5 is absent in the murine 
genome. The authors observed systemically increased 
oxidative stress in the transgenic mice, however, this was 
accompanied by increased mesenteric artery contractility 
and increased expression of contractile markers p-MLC 
and p-MYPT1. One possible explanation for this contra-
diction with our results is that in this model Nox5 expres-
sion occurred also during development. The continued 
presence of Nox5 since early development might render 
different effects than increased expression occurring as 
a result of vascular disease and remodeling in the adult. 
Nevertheless, this study confirms the detrimental effects 
of increased ROS in the vasculature,47 since the authors 
postulate that the uncovered mechanisms are likely 
relevant to the pathology of hypertension. Additionally, 
these results are in line with our conclusion that Nox5 
is a regulator of VSMC phenotype, but the exact effects 
of increased Nox5 are possibly dependent on the physi-
ological context.
Nox5 Is the Connection Between Ca2+ and 
Oxidative Stress
It has been shown before that treating cells with high 
Ca2+ leads to changes in Ca2+ that result in increased 
calcification.21 In this study, we propose uptake via EVs 
as a new mechanism of extracellular Ca2+ influencing 
cytosolic Ca2+ levels. It has been suggested before that 
high Ca2+ can cause increased loading of Ca2+ into EVs.21 
As this effect was blocked by the cytosolic Ca2+ chelator 
BAPTA, Ca2+ uptake into cells was suggested to happen 
before loading into EVs. However, we demonstrate that 
Ca2+ uptake into EVs can happen in the absence of cells. 
We also provide evidence that Ca2+-loaded EVs increase 
cytosolic Ca2+ and that Ca2+ uptake is mediated by clath-
rin- and caveolin-mediated EV uptake. Taken together, 
this suggests that 2 mechanisms of Ca2+ uptake 
exist—EV-dependent and EV-independent, via Ca2+ chan-
nels.6 Interestingly, a recent study, which focused on EVs 
from high-phosphate treated VSMCs demonstrated that 
these EVs induced an increase in cytosolic Ca2+ partially 
via release from cytosolic stores.48 Furthermore, it was 
reported that exosomes bound to autotaxin induced the 
release of Ca2+ from cytosolic stores.49 We did not inves-
tigate the mechanism of Ca2+ elevations in our model. 
However, it is tempting to speculate that these rises in 
cytosolic Ca2+ lead to increased Nox5 activity.
Interestingly, ROS have been shown to increase intra-
cellular Ca2+ by stimulating IP3-mediated Ca2+ mobi-
lization, SERCA (ATPase sarcoplasmic/endoplasmic 
reticulum Ca2+ transporting) inhibition, and by stimulat-
ing Ca2+ channels.43 This has interesting implications for 
Nox5 activation and suggests the presence of a positive 
feedback loop between Ca2+, Nox5, and ROS.
Ca2+ uptake into the arterial vessel wall has been 
shown to be involved in the pathogenesis of arterioscle-
rotic lesions in vivo50 and imbalanced Ca2+ metabolism 
is known to contribute to medial calcification.6 Here, 
we provide a new mechanism by which Ca2+ induces 
VSMC calcification, showing that it plays a role in Nox5-
dependent ROS generation. Thus, we demonstrate that 
increased Ca2+ can induce oxidative stress. These find-
ings have implications for vascular disease, as a mineral 
imbalance in circulation is known to be a manifestation of 
chronic kidney disease, which is accompanied by vascu-
lar calcification.11 Additionally, hitherto advanced glyca-
tion end products and oxidized low-density lipoproteins 
were shown to be the main inducers of oxidative stress in 
the vasculature.29 Although mineral imbalance in chronic 
kidney disease is known to be associated with ROS 
accumulation,51 we demonstrate here that in synthetic 
VSMCs it is Ca2+ itself that contributes to this.
Nox5-Mediated Oxidative Stress Induces EV 
Release and Inhibits Their Re-Uptake
EVs are a well-established factor contributing to vascu-
lar calcification.17,52,53 Our data indicate that EVs alone, 
without cells, are sufficient to induce extracellular matrix 
calcification, demonstrating how potent calcification 
inducers they are.
We show here that phenotypic switching is associ-
ated with changes in EV release. This is consistent with 
previous studies25 where contractile VSMCs showed 
reduced and synthetic VSMCs increased EV release. 
However, our study demonstrates for the first time that 
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Nox5 is the molecular link between Ca2+, oxidative stress 
and EV release. ROS have been shown to promote EV 
release from other cell types,54,55 however, this has not 
been reported in VSMCs before. Interestingly, Ca2+ can 
directly stimulate EV release from cancer cells via Ca2+-
dependent Munc13-4.56 Whether this mechanism is rel-
evant for VSMCs remains to be tested.
It has been shown previously that VSMCs exhibit 
phagocytic capacity24 towards phosphatidylserine 
expressing apoptotic cells and bodies19 and that EVs 
present phosphatidylserine.57 Additionally, it has been 
demonstrated that increased oxidative stress inhibits 
phagocytosis of apoptotic bodies.58 Our results extend 
this effect also to secreted EVs and suggest that the 
increased expression of Nox5 in concert with increased 
Ca2+ levels fuels the production of H2O2 and subse-
quently limits the phagocytic capacity of VSMCs which 
together with increased EV release may culminate in 
increased numbers of EVs in the extracellular matrix.
Limitations and Conclusions
In this study, we used both human and porcine VSMCs. 
Although we established that cells of both species react 
similarly in the experimental conditions in terms of phe-
notypic switching and calcification, we cannot exclude 
the possibility of differences. Most importantly, there are 
species differences in the Nox5 gene with regards to 
isoforms.39,59 It remains to be established which human 
isoforms resemble closest the porcine orthologues.
Another limitation of this study is the use of hepa-
rin, which is known to inhibit EV uptake,60 to induce the 
contractile phenotype in VSMCs. However, in our experi-
ments, cells treated with heparin secreted fewer EVs 
than untreated or synthetic cells. If heparin inhibited EV 
uptake we would expect to observe an accumulation of 
EVs and, therefore, possibly a net increase. That suggests 
that in our model heparin’s EV-blocking activity is weaker 
than contractile phenotype-promoting activity. However, 
it cannot be excluded that decreased EV uptake is con-
nected to maintaining contractile differentiation, as these 
pathways are poorly described in VSMCs.
In conclusion, we showed that switching phenotypes 
to synthetic is required for VSMC calcification, and that in 
synthetic cells increased levels of Ca2+-regulated Nox5 
play a key role in the generation of oxidative stress and 
EV release. Inhibition of VSMC phenotypic switching in 
pathological contexts may be of therapeutic benefit for 
vascular calcification in vivo and this research identifies 
Nox5 as a potential therapeutic target to achieve that.
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